Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 14/20 | 1.00 |
| ▸ | NCF1 | P14598 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121577 | 0.91 | CHKA (1.00) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16121999 | 0.87 | CHKA (0.77) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16095017 | 0.85 | CHKA (0.74) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL17465321 | 0.84 | CHKA (0.87) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL17465323 | 0.84 | CHKA (1.00) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL17465327 | 0.84 | CHKA (0.87) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16121802 | 0.84 | CHKA (0.72) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16102439 | 0.84 | CHKA (0.71) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16121669 | 0.83 | CHKA (0.84) | CHKANCF1CA2PRMT6KDM4E | |
| SCHEMBL16121666 | 0.82 | CHKA (0.82) | CHKANCF1CA2PRMT6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834521-B2 | Choline kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| EP-2968358-A1 | NOVEL CHOLINE KINASE INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151761-A1 | NOVEL CHOLINE KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151761-A1 | NOVEL CHOLINE KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024024-A1 | Novel Choline Kinase Inhibitors | CHKA, CHKB, CEPT1 | CHKA 1/4885NCF1 1251/4885CA2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.